News
Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations
New intellectual property significantly broadens potential patient population for lasofoxifene,...
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer
In preclinical mouse models, results suggested lasofoxifene could be an effective therapy for all...
Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene
IND approval in China allows Shanghai Henlius Biotech, Sermonix’s Chinese development partner for...
Sermonix Pharmaceuticals Announces ‘Menopause’ Journal Publication of Article on Oral Lasofoxifene’s Effects on Vaginal Atrophy in Postmenopausal Women
‘Significant and clinically meaningful’ results support Sermonix’s plans to study oral...
Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape
COLUMBUS, Ohio, Apr. 22, 2024 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces MBC Alliance Membership, New ‘Discover ELAINE’ Website
COLUMBUS, Ohio, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
Partnership expands Henlius’ portfolio with license of exclusive China rights to develop,...
Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life
Most patients minimized or hid side effects from their health care providers for fear of negative...
Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations
COLUMBUS, Ohio, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
To sign up for future Sermonix press releases, please enter your information below.